

Quality Enhancer Value-Based Reimbursement (VBR) Program 2023 - Providers not enrolled in a VBR Medicaid Value-Based Reimbursement Program

CareSource rewards you for excellence. We recognize the outstanding work you're doing to improve your patients' health and quality outcomes every day.

Our **Quality Enhancer Program** rewards you for prioritizing high-value services in your practice.

IMPORTANT PROGRAM DETAILS

With the Quality Enhancer Program, you will receive enhanced reimbursement on selected high value services. All you need to do is submit your claim with the appropriate CPT code, trigger code and modifier and you'll earn an immediate payment. We'll help you find quality metric opportunities through gaps in care reporting.

Quality Measures

The Quality Enhancer Program drives high-value services in your practice by focusing on thirteen target quality measures. Completing services that help meet the following measures will contribute towards your Quality Enhancer payment:

- Well-Child Visits in the First 30 months of Life
- Child and Adolescent Well-Care Visits 3-21 years
- Developmental Screening in the First Three Years of Life
- Screening for Depression
- Social Determinants of Health Screening
- Controlling Blood Pressure
- Comprehensive Diabetes Control < 8% (good control)
- HPV Vaccine
- Meningococcal Vaccine
- Tdap Vaccine
- Rotavirus Vaccine
- Influenza Vaccine
- COVID Vaccine

*Applies to Georgia Families (Medicaid and PeachCare for Kids) members only with CareSource as primary insurance only

Impact Reimbursement and Coding

When you participate in the Quality Enhancer Program, your reimbursement will be based on your submission of claims containing qualifying CPT codes of each target quality measure. The following services and codes qualify for reimbursement in this program:

Measure	Qualifying Service CPT	Trigger Code	Modifier	Reimbursement
*Well-Child Visits in the First 30 Months of Life	99381, 99382, 99391, 99392, 99461	99429	YH	\$10.00/occurrence
*Child and Adolescent Well-Care Visits 3-21 years	99382-99385, 99392-99395	99429	YE	\$10.00/occurrence
*Developmental Screening in the First Three Years of Life	96110	99429	TS	\$10.00/occurrence
**Meningococcal Vaccine	90734, 90619	99429	YI	\$5.00/occurrence
**Tdap Vaccine	90715	99429	YJ	\$5.00/occurrence
**Rotavirus Vaccine	90680, 90681	99429	YK	\$5.00/occurrence
**HPV Vaccine	90649, 90650, 90651	99429	YL	\$5.00/occurrence
*Screening for Depression Ages 12 years and older	G8431, G8510 (HCPCS)	99429	TF	\$5.00/occurrence
Social Determinants of Health Screening	G9920, G9919	99429	YF	\$10.00/occurrence
Controlling High Blood Pressure Ages 18-85 years	CPT II: 3074F, 3075F, 3077F, 3078F, 3079F, 3080F	99429	YM	\$15.00/occurrence
Hemoglobin A1C Control for Patients with Diabetes HbA1c < 8%	HbA1c CPT II: 3044F, 3046F, 3051F, 3052F	99429	YN	\$15.00/occurrence
**Influenza Vaccine	90630, 90653, 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90672, 90673, 90674, 90682, 90685, 90686, 90687, 90688, 90689, 90756	99429	TD	\$10.00/occurrence
**COVID Vaccine	See chart below for vaccine and administration CPT codes	99429	YG	\$10.00/occurrence

*See Telehealth HEDIS measure reference guide for telehealth implications. Telehealth for well-child visits is only allowed for those older than 2 years. AAP recommends birth-2 years as in person visits.

**For vaccine reimbursement, excluding the COVID vaccine, the vaccine CPT code must be billed along with one or more of the following administration CPT codes: 90460, 90471-90474.

You must bill the qualifying service CPT with the trigger code and the modifier to be reimbursed.

COVID-19 Vaccines & Administration Codes					
Revised: January 1, 2023					
Submit claim for administration fee with the appropriate vaccine CPT Code (See NOTE tab for additional instructions)					
#	CPT HCPCS	Vaccine Code Description, Dose	Vaccine Administration Code(s)	Labeler Name	Patient's Age
1	91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	0001A (First Dose) 0002A (Second Dose) 0003A (Third Dose) 0004A (Booster Dose)	Pfizer, Inc.	12 Years & Older
2	91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	0011A (First Dose) 0012A (Second Dose) 0013A (Third Dose)	Moderna, Inc	12 Years & Older
3	91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	0031A (Single Dose) 0034A (Booster Dose)	Janssen	18 Years & Older
4	91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	0041A (1st Dose) 0042A (2nd Dose) 0044A (Booster Dose)	Novavax	12 Years & Older 18 Years & Older
5	91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	0051A (First Dose) 0052A (Second Dose) 0053A (Third Dose) 0054A (Booster Dose)	Pfizer, Inc.	12 Years & Older
6	91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	0064A (Booster Dose)	Moderna	18 Years & Older
7	91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris- sucrose formulation, for intramuscular use	0071A (First Dose) 0072A (Second Dose) 0073A (Third Dose) 0074A (Booster Dose)	Pfizer, Inc.	5-11 Years Old
8	91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0081A (1st Dose) 0082A (2nd Dose) 0083A (3rd Dose)	Pfizer, Inc.	6 Months - 4 Years
9	91309	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0091A (1st Dose) 0092A (2nd Dose) 0093A (3rd Dose) 0094A (Booster)	Moderna, Inc	6 - 11 Years 18 Years & older
10	91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0111A (1st Dose) 0112A (2nd Dose) 0113A (3rd Dose)	Moderna, Inc	6 Months - 5 Years
11	91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use	0124A (Booster)	Pfizer, Inc.	12 Years & older
12	91313	Severe acute respiratory syndrome coronavirus 2 (SARS - CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA - LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	0134A (Booster)	Moderna, Inc	18 Years & older
13	91314	Severe acute respiratory syndrome coronavirus 2 (SARS - CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA - LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	0144A (Booster)	Moderna, Inc	6 - 11 Years

14	91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	0154A (Booster)	Pfizer, Inc.	5 - 11 Years
15	91316	Severe acute respiratory syndrome coronavirus 2 (SARS - CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA - LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use	0164A (Booster)	Moderna, Inc	6 months through 5 years
16	91317	Severe acute respiratory syndrome coronavirus 2 (SARS - CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA - LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris -sucrose formulation, for intramuscular use	00173A (3rd Dose)	Pfizer, Inc.	6 months through 4 years
17	M0201	Covid-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only covid-19 vaccine administration is performed at the patient's home	N/A	N/A	N/A

Modifications

CareSource reserves the right to modify the program on an annual basis. Notice will be provided of any changes ninety (90) days prior to the effective date of the modification.

Get Engaged Today

Getting started with CareSource's **Quality Enhancer Program** is the next step towards earning the rewards you deserve. This program will initiate 90 days after receiving this notification.

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).